title: Unrelated donor bone marrow transplantation for children with acute leukemia.
abstract: OBJECTIVE
  To test the use of unrelated donor bone marrow transplantation (URD BMT) to cure children with high-risk acute leukemias.
  
  
  METHODS
  Between June 1985 and December 1994, 50 children with acute leukemia (15 acute myelogenous leukemia [AML], 35 acute lymphoblastic leukemia [ALL]; 22 greater than second complete remission [CR]) received BMT from a URD at the University of Minnesota. Ages ranged from 0.9 to 17.5 years (median, 8.8). Median follow-up is 2.1 years (range, 1 to 7.3). Thirty patients (60%) received bone marrow fully matched at HLA-A,B and DRB1; 20 (40%) received bone marrow with a major or minor mismatch at a single HLA-A or B locus.
  
  
  RESULTS
  The median time to neutrophil engraftment was day 24 (range, 14 to 42 days) in those receiving matched and day 25 (range, 15 to 32 days) in those receiving mismatched marrow (P = .35). The incidence of grades III to IV graft-versus-host disease (GVHD) was 23% (95% confidence interval [CI], 7% to 39%) in matched and 32% (95% CI, 8% to 52%) in HLA-mismatched patients (P = .57). The incidence of chronic GVHD was 50% (95% CI, 28% to 72%) in matched and 57% (95% CI, 23% to 91%) in mismatched patients (P = .80). Disease-free survival for patients with ALL is 37% (95% CI, 21% to 53%) at 1 year and 30% (95% CI, 15% to 46%) at 2 years; for patients with AML, 53% (95% CI, 28% to 78%) at 1 year and 33% (95% CI, 6% to 60%) at 2 years.
  
  
  CONCLUSIONS
  URD BMT is an effective treatment for children with poor-prognosis acute leukemia and should be considered for all high-risk patients. Early referral of patients is strongly recommended.
authors.affiliation: Department of Pediatrics, University of Minnesota, Minneapolis 55455, USA. davie008@maroon.tc.umn.edu
authors.forename: S M
authors.initials: SM
authors.lastname: Davies
authors.forename: J E
authors.initials: JE
authors.lastname: Wagner
authors.forename: X O
authors.initials: XO
authors.lastname: Shu
authors.forename: B R
authors.initials: BR
authors.lastname: Blazar
authors.forename: E
authors.initials: E
authors.lastname: Katsanis
authors.forename: P J
authors.initials: PJ
authors.lastname: Orchard
authors.forename: J H
authors.initials: JH
authors.lastname: Kersey
authors.forename: K E
authors.initials: KE
authors.lastname: Dusenbery
authors.forename: D J
authors.initials: DJ
authors.lastname: Weisdorf
authors.forename: P B
authors.initials: PB
authors.lastname: McGlave
authors.forename: N K
authors.initials: NK
authors.lastname: Ramsay
mesh_terms: D000293:Adolescent; D016026:Bone Marrow Transplantation / Q000009:adverse effects; D002648:Child; D002675:Child, Preschool; D018572:Disease-Free Survival; D005260:Female; D006086:Graft vs Host Disease / Q000209:etiology; D006801:Humans; D007223:Infant; D015470:Leukemia, Myeloid, Acute / Q000628:therapy*; D008297:Male; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000628:therapy*; D011379:Prognosis; D012306:Risk; D012720:Severity of Illness Index; D016019:Survival Analysis; D014184:Transplantation, Homologous; D016896:Treatment Outcome